Passage Bio Statistics

Total Valuation

Passage Bio has a market cap or net worth of $83.21 million. The enterprise value is $5.17 million.

Market Cap	83.21M
Enterprise Value	5.17M

Important Dates

The last earnings date was Tuesday, May 14, 2024, before market open.

Earnings Date	May 14, 2024
Ex-Dividend Date	n/a

Share Statistics

Passage Bio has 61.64 million shares outstanding. The number of shares has increased by 3.07% in one year.

Shares Outstanding	61.64M
Shares Change (YoY)	+3.07%
Shares Change (QoQ)	+2.58%
Owned by Insiders (%)	0.49%
Owned by Institutions (%)	63.48%
Float	37.34M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	0.79
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 8.43, with a Debt / Equity ratio of 0.25.

Current Ratio	8.43
Quick Ratio	n/a
Debt / Equity	0.25
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -68.50% and return on invested capital (ROIC) is -64.28%.

Return on Equity (ROE)	-68.50%
Return on Assets (ROA)	-51.60%
Return on Capital (ROIC)	-64.28%
Revenue Per Employee	n/a
Profits Per Employee	-$1.46M
Employee Count	58
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +34.42% in the last 52 weeks. The beta is 1.27, so Passage Bio's price volatility has been higher than the market average.

Beta (1Y)	1.27
52-Week Price Change	+34.42%
50-Day Moving Average	1.34
200-Day Moving Average	0.97
Relative Strength Index (RSI)	47.80
Average Volume (30 Days)	312,100

Short Selling Information

The latest short interest is 1.76 million, so 2.85% of the outstanding shares have been sold short.

Short Interest	1.76M
Short Previous Month	1.75M
Short % of Shares Out	2.85%
Short % of Float	4.71%
Short Ratio (days to cover)	12.68

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-84.44M
Pretax Income	-84.44M
Net Income	-84.44M
EBITDA	-80.89M
EBIT	-84.44M
Earnings Per Share (EPS)	-$1.53

Full Income Statement

Balance Sheet

The company has $104.53 million in cash and $26.48 million in debt, giving a net cash position of $78.05 million or $1.27 per share.

Cash & Cash Equivalents	104.53M
Total Debt	26.48M
Net Cash	78.05M
Net Cash Per Share	$1.27
Equity / Book Value	104.88M
Book Value Per Share	1.70
Working Capital	95.45M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$74.75 million and capital expenditures -$120,000, giving a free cash flow of -$74.87 million.

Operating Cash Flow	-74.75M
Capital Expenditures	-120,000
Free Cash Flow	-74.87M
FCF Per Share	-$1.33

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Passage Bio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-3.07%
Shareholder Yield	-3.07%
Earnings Yield	-101.47%
FCF Yield	-89.97%

Analyst Forecast

The average price target for Passage Bio is $9.00, which is 581.82% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$9.00
Price Target Difference	581.82%
Analyst Consensus	Strong Buy
Analyst Count	3
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2